{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:16:18Z","timestamp":1783692978797,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00280-023-04530-x","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:02:36Z","timestamp":1682348556000},"page":"457-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India"],"prefix":"10.1007","volume":"91","author":[{"given":"Ankit","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanashyam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajnish","family":"Nagarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodhisatta","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Samal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Meshram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kaushal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. T.","family":"Satheesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravikumar","family":"Wategaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasi Viswanathan","family":"Thiagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartikeya","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vijayaveeran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuphan Kanti","family":"Dolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minish","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Hingmire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara Chand","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. C.","family":"Lakshmaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepan","family":"Rajamanickam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Nemade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Mahato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7440-5647","authenticated-orcid":false,"given":"Sanjeev Kumar","family":"Mendiratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maulik","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"issue":"45","key":"4530_CR1","doi-asserted-by":"publisher","first-page":"e8494","DOI":"10.1097\/MD.0000000000008494","volume":"96","author":"H Xin","year":"2017","unstructured":"Xin H, Zeng M, Yang S et al (2017) Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma. Medicine 96(45):e8494","journal-title":"Medicine"},{"issue":"3","key":"4530_CR2","first-page":"148","volume":"35","author":"E Dotan","year":"2010","unstructured":"Dotan E, Aggarwal C, Smith M (2010) Impact of Rituximab (Rituxan) on the Treatment of B-cell Non-Hodgkin\u2019s Lymphoma. Pharm Ther 35(3):148\u2013157","journal-title":"Pharm Ther"},{"key":"4530_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.14136","volume":"174","author":"S Chaganti","year":"2016","unstructured":"Chaganti S, Illidge T, Barrington S et al (2016) Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol 174:43\u201356","journal-title":"Br J Haematol"},{"key":"4530_CR4","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U et al (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v116\u2013v125","journal-title":"Ann Oncol"},{"key":"4530_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","volume":"12","author":"AD Zelenetz","year":"2014","unstructured":"Zelenetz AD, Gordon LI, Wierda WG et al (2014) Non-Hodgkin\u2019s lymphomas, version 4.2014. J Natl Compr Canc Netw 12:1282\u20131303","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"4530_CR6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","volume":"70","author":"GM Keating","year":"2010","unstructured":"Keating GM (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70(11):1445\u20131476","journal-title":"Drugs"},{"key":"4530_CR7","unstructured":"Biosimilar and Interchangeable Biologics: More Treatment Choices. https:\/\/www.fda.gov\/consumers\/consumer-updates\/biosimilar-and-interchangeable-biologics-more-treatment-choices."},{"issue":"5","key":"4530_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD et al (2007) IWG revised response criteria for malignant lymphoma: special article. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"key":"4530_CR9","volume-title":"Guideline on bioanalytical method validation (EMEA\/CHMP\/EWP\/192217\/2009)","author":"Committee for Medicinal Products for Human Use","year":"2018","unstructured":"Committee for Medicinal Products for Human Use (2018) Guideline on bioanalytical method validation (EMEA\/CHMP\/EWP\/192217\/2009). European medicines Agency, London"},{"key":"4530_CR10","unstructured":"US Food and Drug Administration. (2012). Guidance for industry. Bioanalytical method validation."},{"key":"4530_CR11","unstructured":"EMA. (2017). Guideline on Immunogenicity assessment of therapeutic proteins. EMEA\/CHMP\/BMWP\/14327\/2006 Rev 1"},{"key":"4530_CR12","unstructured":"FDA. (2019). Immunogenicity Testing of Therapeutic Protein Products \u2014 Developing and Validating Assays for Anti-Drug Antibody Detection. Guidance for Industry."},{"key":"4530_CR13","doi-asserted-by":"publisher","DOI":"10.4103\/ASJO.ASJO_29_16","author":"PD Apsangikar","year":"2017","unstructured":"Apsangikar PD, Chaudhary S, Naik MM, Kozgi P (2017) A phase III, multicentric, open-label, two-arm, parallel group, active-control, randomized, comparative clinical study to evaluate efficacy and safety of RituxiRel\u2122 arm (rituximab) with reference arm (rituximab) in patients with non-Hodgkin\u2019s lymphoma. Asian J Oncol. https:\/\/doi.org\/10.4103\/ASJO.ASJO_29_16","journal-title":"Asian J Oncol"},{"key":"4530_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.19.00248","author":"A Viswabandya","year":"2019","unstructured":"Viswabandya A, Shah S, Mukhopadhyay A et al (2019) Randomized, double-blind, pharmacokinetic equivalence trial comparing DRL-rituximab with MabThera in patients with diffuse large B-cell lymphoma. J Global Oncol. https:\/\/doi.org\/10.1200\/JGO.19.00248","journal-title":"J Global Oncol"},{"issue":"14","key":"4530_CR15","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1080\/10428194.2019.1633632","volume":"60","author":"M Candelaria","year":"2019","unstructured":"Candelaria M, Gonz\u00e1lez DE, Delamain MT et al (2019) Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Leuk Lymphoma 60(14):3375\u20133385. https:\/\/doi.org\/10.1080\/10428194.2019.1633632","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"4530_CR16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A et al (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5(6):826\u2013837","journal-title":"MAbs"},{"key":"4530_CR17","unstructured":"Ristova Product Information IND. January 2021. Ro 45\u20132294."},{"key":"4530_CR18","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","volume":"378","author":"C Recher","year":"2011","unstructured":"Recher C, Coiffier B, Haioun C et al (2011) Intensifi ed chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diff use large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 378:1858\u20131867","journal-title":"Lancet"},{"key":"4530_CR19","first-page":"38","volume":"13","author":"Y Shi","year":"2020","unstructured":"Shi Y, Song Y, Qin Y et al (2020) A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. J HematolOncol 13:38","journal-title":"J HematolOncol"},{"key":"4530_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","volume":"81","author":"M Candelaria","year":"2018","unstructured":"Candelaria M, Gonzalez D, Gomez FJF et al (2018) Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83\u2122, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. Cancer Chemother Pharmacol 81:515\u2013527","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04530-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:46:58Z","timestamp":1744159618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04530-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["4530"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04530-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Sanjeev Kumar Mendiratta and Dr Maulik Doshi are the employees of Zydus Lifesciences Limited. All other authors declared to have no conflict of interest. The members of the study investigators\u2019 group (i.e., Dr Ankit Patel, Dr Niraj Bhatt, Dr S S Prakash , Dr Ghanashyam Biswas, Dr Rajnish Nagarkar, Dr Bodhisatta Roy, Dr Priyanka Samal, Dr Narendra Agrawal, Dr Sushil Meshram, Dr Ashish Kaushal, Dr C T Satheesh, Dr Ravikumar Wategaonkar, Dr Kasi Viswanathan Thiagarajan, Dr Kartikeya Jain, Dr P Vijayaveeran, Dr Kalyan Mukherjee, Dr Kishore Singh, Dr Tushar Patil, Dr Amit Jain, Dr Tuphan Kanti Dolai, Dr Minish Jain, Dr Sachin Hingmire, Dr Tara Chand Gupta, Dr K C Lakshmaiah, Dr Deepan Rajamanickam, Dr Bhushan Nemade, Dr Vikash Goyal and Dr Pinaki Mahato) were compensated by the sponsor (Zydus Lifesciences Limited) for conducting the study at their respective study sites. No other potential conflicts of interest were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all subjects at the time of screening. This trial was initiated after obtaining the approvals of ECs, DCGI and registering the trial with the CTRI. This trial was conducted in accordance with the applicable local regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}